SynthesisAnnals of surgical oncology2026
Cytoreductive Surgery With or Without HITHOC for Pleural Mesothelioma: A Meta-analysis of Survival and Perioperative Outcomes.
Synthesis in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPleural mesothelioma (PM) is a rare and aggressive malignancy with limited overall survival (OS) despite multimodal therapy. Cytoreductive surgery is the standard of care for selected patients. However, locoregional recurrence remains common. Hyperthermic intrathoracic chemotherapy (HITHOC) has been proposed as an adjunct to enhance local disease control.
methodsA systematic review and meta-analysis were performed according to PRISMA guidelines and registered in PROSPERO (CRD420251132268). This study searched PubMed, Embase, and Cochrane Library up to 18 July 2025. Pooled hazard ratios (HRs), odds ratios (ORs), and mean differences (MDs) were calculated using random-effects models. Individual patient data (IPD) were reconstructed to generate Kaplan-Meier curves.
resultsSix studies comprising 1060 patients were included. Of these patients, 490 (46.2%) received HITHOC and 570 (53.8%) underwent surgery without HITHOC. Overall survival analysis showed a significant survival benefit for HITHOC (HR, 0.82; 95% confidence interval [CI] 0.71-0.94). The median OS was 21.3 months (95% CI, 19.2-24.9 months) in the HITHOC group versus 18.8 months (95% CI, 17.5-20.9 months) in the non-HITHOC group. No statistically significant differences were found for 30-day mortality (OR, 0.53; 95% CI, 0.16-1.05), 90-day mortality (OR, 0.49; 95% CI, 0.24-1.01), bronchopleural fistula/empyema (OR, 0.55; 95% CI, 0.07-4.12), arrhythmia (OR, 1.17; 95% CI, 0.45-3.06), or hospital length of stay (MD, 0.38 days; 95% CI, -4.61 to 5.37 days).
conclusionFor patients undergoing cytoreductive surgery for pleural mesothelioma, HITHOC is associated with a significant improvement in OS without increased early postoperative risk. These findings support the use of HITHOC in specialized centers with appropriate surgical expertise and patient selection.
Indexed as
Identifiers
41838360What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.